Evaluating the Association of Initial Benzodiazepine Use and Antidepressant Adherence among Adults with Anxiety Disorders

Chung Hsuen Wu, Joel F. Farley, Bradley N. Gaynes

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The purpose of this study was to evaluate whether co-prescription of benzodiazepine when initiating antidepressant treatment is associated with better antidepressant adherence than initiating treatment with antidepressants alone among patients with anxiety disorders. Methods: We conducted a retrospective observational cohort study using MarketScan Commercial Claims and Encounters database (Thomson Reuters). We identified patients aged 18-64 with anxiety disorders (including generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder), who were newly receiving a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor between July 1, 2005 and June 30, 2007. We compared those who were co-prescribed a benzodiazepine at antidepressant initiation with those who begun on an antidepressant alone. The outcome measure was antidepressant adherence rate measured as the proportion of days covered (PDC) on antidepressant treatment. Patients with PDC ≥80% were considered adherent. We used propensity score matching to balance measurable confounders. Logistic regression models were used to measure adherence. Results: Our study included 6949 patients who were co-prescribed benzodiazepines and antidepressants, and 6949 patients receiving antidepressants alone after matching for propensity scores. Before adjusting covariates, patients in the co-prescribed benzodiazepine group had lower adherence to antidepressants (PDC: 0.52 vs. 0.60, p <0.01). After adjusting the covariates, we found that patients in the co-prescribed benzodiazepine group were less likely to adhere to antidepressant treatment (odds ratio = 0.70; 95% confidence interval = 0.65-0.75) when compared with patients using antidepressants alone. Conclusion: This is the largest analysis with an observational study design to date. Our study results showed that patients with anxiety who are co-prescribed benzodiazepines when initiating treatment with antidepressants are less likely to adhere to antidepressants than those who begin treatment with antidepressants alone. Further research should clarify whether co-prescribing benzodiazepines with antidepressant initiators is a preferred clinical strategy for those with anxiety disorders.

Original languageEnglish
Pages (from-to)338-344
Number of pages7
JournalJournal of Experimental and Clinical Medicine(Taiwan)
Volume4
Issue number6
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Anxiety Disorders
Benzodiazepines
Antidepressive Agents
Propensity Score
Observational Studies
Therapeutics
Logistic Models
Panic Disorder
Obsessive-Compulsive Disorder
Serotonin Uptake Inhibitors
Post-Traumatic Stress Disorders
Prescriptions

Keywords

  • Adherence
  • Antidepressant
  • Anxiety disorders
  • Benzodiazepine
  • Claims data

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Evaluating the Association of Initial Benzodiazepine Use and Antidepressant Adherence among Adults with Anxiety Disorders. / Wu, Chung Hsuen; Farley, Joel F.; Gaynes, Bradley N.

In: Journal of Experimental and Clinical Medicine(Taiwan), Vol. 4, No. 6, 12.2012, p. 338-344.

Research output: Contribution to journalArticle

@article{dbf6aa497e4b496db23a225cdbded042,
title = "Evaluating the Association of Initial Benzodiazepine Use and Antidepressant Adherence among Adults with Anxiety Disorders",
abstract = "Objective: The purpose of this study was to evaluate whether co-prescription of benzodiazepine when initiating antidepressant treatment is associated with better antidepressant adherence than initiating treatment with antidepressants alone among patients with anxiety disorders. Methods: We conducted a retrospective observational cohort study using MarketScan Commercial Claims and Encounters database (Thomson Reuters). We identified patients aged 18-64 with anxiety disorders (including generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder), who were newly receiving a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor between July 1, 2005 and June 30, 2007. We compared those who were co-prescribed a benzodiazepine at antidepressant initiation with those who begun on an antidepressant alone. The outcome measure was antidepressant adherence rate measured as the proportion of days covered (PDC) on antidepressant treatment. Patients with PDC ≥80{\%} were considered adherent. We used propensity score matching to balance measurable confounders. Logistic regression models were used to measure adherence. Results: Our study included 6949 patients who were co-prescribed benzodiazepines and antidepressants, and 6949 patients receiving antidepressants alone after matching for propensity scores. Before adjusting covariates, patients in the co-prescribed benzodiazepine group had lower adherence to antidepressants (PDC: 0.52 vs. 0.60, p <0.01). After adjusting the covariates, we found that patients in the co-prescribed benzodiazepine group were less likely to adhere to antidepressant treatment (odds ratio = 0.70; 95{\%} confidence interval = 0.65-0.75) when compared with patients using antidepressants alone. Conclusion: This is the largest analysis with an observational study design to date. Our study results showed that patients with anxiety who are co-prescribed benzodiazepines when initiating treatment with antidepressants are less likely to adhere to antidepressants than those who begin treatment with antidepressants alone. Further research should clarify whether co-prescribing benzodiazepines with antidepressant initiators is a preferred clinical strategy for those with anxiety disorders.",
keywords = "Adherence, Antidepressant, Anxiety disorders, Benzodiazepine, Claims data",
author = "Wu, {Chung Hsuen} and Farley, {Joel F.} and Gaynes, {Bradley N.}",
year = "2012",
month = "12",
doi = "10.1016/j.jecm.2012.10.007",
language = "English",
volume = "4",
pages = "338--344",
journal = "Journal of Experimental and Clinical Medicine",
issn = "1878-3317",
publisher = "Elsevier Taiwan LLC",
number = "6",

}

TY - JOUR

T1 - Evaluating the Association of Initial Benzodiazepine Use and Antidepressant Adherence among Adults with Anxiety Disorders

AU - Wu, Chung Hsuen

AU - Farley, Joel F.

AU - Gaynes, Bradley N.

PY - 2012/12

Y1 - 2012/12

N2 - Objective: The purpose of this study was to evaluate whether co-prescription of benzodiazepine when initiating antidepressant treatment is associated with better antidepressant adherence than initiating treatment with antidepressants alone among patients with anxiety disorders. Methods: We conducted a retrospective observational cohort study using MarketScan Commercial Claims and Encounters database (Thomson Reuters). We identified patients aged 18-64 with anxiety disorders (including generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder), who were newly receiving a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor between July 1, 2005 and June 30, 2007. We compared those who were co-prescribed a benzodiazepine at antidepressant initiation with those who begun on an antidepressant alone. The outcome measure was antidepressant adherence rate measured as the proportion of days covered (PDC) on antidepressant treatment. Patients with PDC ≥80% were considered adherent. We used propensity score matching to balance measurable confounders. Logistic regression models were used to measure adherence. Results: Our study included 6949 patients who were co-prescribed benzodiazepines and antidepressants, and 6949 patients receiving antidepressants alone after matching for propensity scores. Before adjusting covariates, patients in the co-prescribed benzodiazepine group had lower adherence to antidepressants (PDC: 0.52 vs. 0.60, p <0.01). After adjusting the covariates, we found that patients in the co-prescribed benzodiazepine group were less likely to adhere to antidepressant treatment (odds ratio = 0.70; 95% confidence interval = 0.65-0.75) when compared with patients using antidepressants alone. Conclusion: This is the largest analysis with an observational study design to date. Our study results showed that patients with anxiety who are co-prescribed benzodiazepines when initiating treatment with antidepressants are less likely to adhere to antidepressants than those who begin treatment with antidepressants alone. Further research should clarify whether co-prescribing benzodiazepines with antidepressant initiators is a preferred clinical strategy for those with anxiety disorders.

AB - Objective: The purpose of this study was to evaluate whether co-prescription of benzodiazepine when initiating antidepressant treatment is associated with better antidepressant adherence than initiating treatment with antidepressants alone among patients with anxiety disorders. Methods: We conducted a retrospective observational cohort study using MarketScan Commercial Claims and Encounters database (Thomson Reuters). We identified patients aged 18-64 with anxiety disorders (including generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder), who were newly receiving a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor between July 1, 2005 and June 30, 2007. We compared those who were co-prescribed a benzodiazepine at antidepressant initiation with those who begun on an antidepressant alone. The outcome measure was antidepressant adherence rate measured as the proportion of days covered (PDC) on antidepressant treatment. Patients with PDC ≥80% were considered adherent. We used propensity score matching to balance measurable confounders. Logistic regression models were used to measure adherence. Results: Our study included 6949 patients who were co-prescribed benzodiazepines and antidepressants, and 6949 patients receiving antidepressants alone after matching for propensity scores. Before adjusting covariates, patients in the co-prescribed benzodiazepine group had lower adherence to antidepressants (PDC: 0.52 vs. 0.60, p <0.01). After adjusting the covariates, we found that patients in the co-prescribed benzodiazepine group were less likely to adhere to antidepressant treatment (odds ratio = 0.70; 95% confidence interval = 0.65-0.75) when compared with patients using antidepressants alone. Conclusion: This is the largest analysis with an observational study design to date. Our study results showed that patients with anxiety who are co-prescribed benzodiazepines when initiating treatment with antidepressants are less likely to adhere to antidepressants than those who begin treatment with antidepressants alone. Further research should clarify whether co-prescribing benzodiazepines with antidepressant initiators is a preferred clinical strategy for those with anxiety disorders.

KW - Adherence

KW - Antidepressant

KW - Anxiety disorders

KW - Benzodiazepine

KW - Claims data

UR - http://www.scopus.com/inward/record.url?scp=84871444930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871444930&partnerID=8YFLogxK

U2 - 10.1016/j.jecm.2012.10.007

DO - 10.1016/j.jecm.2012.10.007

M3 - Article

AN - SCOPUS:84871444930

VL - 4

SP - 338

EP - 344

JO - Journal of Experimental and Clinical Medicine

JF - Journal of Experimental and Clinical Medicine

SN - 1878-3317

IS - 6

ER -